GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » Institutional Ownership

SQI Diagnostics (FRA:XSQ) Institutional Ownership : 0.99% (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SQI Diagnostics's institutional ownership is 0.99%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SQI Diagnostics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SQI Diagnostics's Float Percentage Of Total Shares Outstanding is 0.00%.


SQI Diagnostics Institutional Ownership Historical Data

The historical data trend for SQI Diagnostics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics Institutional Ownership Chart

SQI Diagnostics Historical Data

The historical data trend for SQI Diagnostics can be seen below:

2020-10-31 2020-11-30 2020-12-31 2021-01-31 2021-02-28 2021-03-31 2021-04-30 2021-05-31 2021-06-30 2021-07-31
Institutional Ownership 1.17 1.17 1.09 1.09 1.09 1.05 1.05 1.05 0.99 0.99

SQI Diagnostics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SQI Diagnostics (FRA:XSQ) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines